Skip to Content Skip to Search

Analyst consensus

The consensus estimates are collected by the company and based on the estimates of brokerage firms covering GlaxoSmithKline. Please ensure you have read and acknowledged the disclaimer prior to reviewing the information provided.

FY2020-2024 figures are as at 03/09/2020

Please select...
£m (unless stated) 2020 2021 2022 2023 2024 2020-2024 n=
Turnover 34,978 36,024 37,372 38,723 40,500 10
Cost of sales (10,370) (10,589) (10,888) (11,186) (11,629) 10
Selling, general and administration (11,005) (11,164) (11,369) (11,594) (11,899) 10
Research and Development (4,724) (5,092) (5,269) (5,415) (5,613) 10
Royalty income 309 318 340 358 175 10
Operating profit 9,189 9,497 10,185 10,885 11,535 10
Net finance costs (850) (834) (806) (766) (739) 10
Associates 37 26 26 26 25 10
Profit before tax 8,377 8,688 9,405 10,145 10,821 10
Taxation (1,362) (1,568) (1,773) (1,923) (2,059) 10
Profit after tax  7,014 7,120 7,631 8,221 8,762 10
Minority interests (1,148) (1,199) (1,266) (1,312) (1,346) 10
Profit attributable to shareholders 5,866 5,921 6,365 6,909 7,415 10
WANS (m) 4,973 4,988 5,005 5,023 5,030 10
Earnings per share (p) 118.0 118.7 127.2 137.5 147.4 10
Dividend per share (p) 80.0 80.1 80.9 81.9 83.2 9
Free Cash Flow 5,005 4,904 5,637 6,518 6,987 8
Net Debt (22,192) (21,222) (19,957) (17,843) (15,624) 9

The firms included are: Barclays, Citi, Credit Suisse, Goldman Sachs, Guggenheim Securities, Morgan Stanley, Redburn, SVB Leerink, UBS, Wolfe Research

Turnover £m 2020 2021 2022 2023 2024 2020-2024 n=
Anoro 557 595 628 657 682 10
Arnuity 47 50 51 52 53 10
Incruse 255 275 289 302 315 10
Relvar/Breo 1,034 1,044 1,062 1,073 1,085 10
Trelegy 838 1,117 1,358 1,565 1,734 10
Ellipta portfolio 2,729 3,081 3,388 3,649 3,869 10
Nucala 960 1,075 1,162 1,231 1,285 10
Total Respiratory 3,689 4,156 4,550 4,880 5,153 10
             
Tivicay 1,605 1,554 1,496 1,431 1,379 8
Triumeq 2,337 2,187 2,078 1,986 1,901 8
Juluca 504 606 673 717 744 10
Dovato 303 566 849 1,068 1,249 10
Dolutegravir based regimens 4,741 4,882 5,041 5,120 5,162 10
Cabotegravir +/- rilpivirine 5 89 219 367 523 10
Rukobia (fostemsavir) 16 74 136 190 231 7
Epzicom/Kivexa 39 30 24 21 17 10
HIV 4,926 5,162 5,468 5,720 5,943 10
             
Benylsta 721 821 916 990 1,051 10
             
Zejula 358 518 671 802 922 10
             
Advair (US) 411 272 221 188 170 10
Seretide (ex US) 1,105 963 859 776 712 10
Seretide/Advair 1,516 1,235 1,081 964 882 10
Flixotide/Flovent 532 504 481 458 438 10
Ventolin 700 599 562 538 517 10
Avamys/Veramyst 308 309 307 262 238 9
Established Respiratory 3,308 2,891 2,664 2,450 2,294 10
Other Established Pharmaceuticals 4,416 4,174 3,978 3,787 3,638 10
Established Pharmaceuticals 7,724 7,065 6,642 6,236 5,932 10
             
Blenrep (belantamab mafodotin) 43 155 291 457 631 10
dostarlimab 26 81 155 243 319 8
daprodustat - 18 73 159 241 8
             
Pharmaceuticals 17,483 17,961 18,780 19,605 20,474 10

The firms included are: Barclays, Citi, Credit Suisse, Goldman Sachs, Guggenheim Securities, Morgan Stanley, Redburn, SVB Leerink, UBS, Wolfe Research

Turnover £m 2020 2021 2022 2023 2024 2020-2024 n=
Bexsero 654 714 752 781 802 9
Menveo 256 267 279 288 295 9
Fluarix/Flulaval 572 592 613 632 649 10
Shingrix 2,224 2,546 2,681 2,856 3,407 10
Boostrix 522 541 553 562 569 9
Cervarix 59 54 53 53 53 9
Hepatitis 624 695 735 754 767 9
Infanrix, Pediarix 677 683 686 687 691 9
Rotarix 584 593 604 615 626 9
Synflorix 470 474 474 469 458 9
Vaccines 7,116 7,682 7,963 8,237 8,884 10

The firms included are: Barclays, Citi, Credit Suisse, Goldman Sachs, Guggenheim Securities, Morgan Stanley, Redburn, SVB Leerink, UBS, Wolfe Research

Turnover £m 2020 2021 2022 2023 2024 2020-2024 n=
Oral Care 2,788 2,893 2,995 3,100 3,204 6
Pain Relief 2,198 2,285 2,365 2,449 2,535 6
Respiratory health 1,377 1,425 1,466 1,501 1,537 6
VMS 1,421 1,483 1,534 1,577 1,622 6
Digestive Health and other 1,855 1,904 1,955 2,008 2,063 6
Brands divested and under review 715 372 295 226 162 6
Consumer Health 10,353 10,362 10,611 10,862 11,123 10

The firms included are: Barclays, Citi, Credit Suisse, Goldman Sachs, Guggenheim Securities, Morgan Stanley, Redburn, SVB Leerink, UBS, Wolfe Research

Back to top